Tharimmune (NASDAQ:THAR) Trading Up 3.8% – Time to Buy?

Tharimmune, Inc. (NASDAQ:THAR) shares were up 3.8% during mid-day trading on Monday . The stock traded as high as $4.88 and last traded at $4.68. Approximately 798,582 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 1,476,877 shares. The stock had previously closed at $4.51.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tharimmune in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Tharimmune Stock Up 3.8%

The firm has a market cap of $176.58 million, a P/E ratio of -1.17 and a beta of 1.43. The firm has a fifty day moving average of $3.52 and a 200-day moving average of $3.25.

Hedge Funds Weigh In On Tharimmune

Hedge funds and other institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC acquired a new position in shares of Tharimmune during the 4th quarter worth approximately $9,854,000. Clear Street Group Inc. acquired a new position in shares of Tharimmune in the fourth quarter valued at $5,066,000. Feynman Point Asset Management LLC acquired a new position in shares of Tharimmune in the fourth quarter valued at $1,314,000. Marshall Wace LLP bought a new position in shares of Tharimmune in the fourth quarter valued at about $1,030,000. Finally, Geode Capital Management LLC lifted its stake in shares of Tharimmune by 1,102.6% during the 4th quarter. Geode Capital Management LLC now owns 335,923 shares of the company’s stock worth $1,018,000 after buying an additional 307,991 shares during the last quarter. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.